Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. Frisell T, Hedberg S, Piehl F. Ann Neurol 2026 Jun 17. doi: 10.1002/ana.78286.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Frisell T, Hedberg S, Piehl F. Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. Ann Neurol 2026 Jun 17. doi: 10.1002/ana.78286.
PMID: 42310849